Transplantation of a liver segment from a mutation heterozygous living donor effectively controls classical maple syrup urine disease (MSUD).
Living related versus deceased donor transplants for MSUD result in similar but not identical metabolic outcomes.
Live donor liver transplantation for MSUD improves access to effective treatment in resource-limited clinical settings.
Through the domino procedure, live donor transplant adds a new liver to the donor pool.